For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Health tech sees strong start to 2025 with five $100M+ funding rounds, including Evergreen Nephrology, Qventus, ...
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.
Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about ...
Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback